Cost considerations regarding the prospective surveillance model for breast cancer survivors.
Identifieur interne : 004403 ( Main/Exploration ); précédent : 004402; suivant : 004404Cost considerations regarding the prospective surveillance model for breast cancer survivors.
Auteurs : Andrea L. Cheville [États-Unis] ; John A. Nyman ; Sandhya Pruthi ; Jeffrey R. BasfordSource :
- Cancer [ 1097-0142 ] ; 2012.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Analyse coût-bénéfice, Congrès comme sujet, Coûts des soins de santé, Femelle, Humains, Lymphoedème (rééducation et réadaptation), Lymphoedème (économie), Lymphoedème (étiologie), Maladies ostéomusculaires (rééducation et réadaptation), Maladies ostéomusculaires (économie), Maladies ostéomusculaires (étiologie), Mobilité réduite, Société américaine du cancer, Sujet âgé, Survivants, Techniques de physiothérapie (économie), Tumeurs du sein (), Tumeurs du sein (diagnostic), Tumeurs du sein (rééducation et réadaptation), États-Unis d'Amérique, Études longitudinales, Études prospectives, Évaluation de l'incapacité.
- MESH :
- diagnostic : Tumeurs du sein.
- rééducation et réadaptation : Lymphoedème, Maladies ostéomusculaires, Tumeurs du sein.
- économie : Lymphoedème, Maladies ostéomusculaires, Techniques de physiothérapie.
- étiologie : Lymphoedème, Maladies ostéomusculaires.
- Adulte, Adulte d'âge moyen, Analyse coût-bénéfice, Congrès comme sujet, Coûts des soins de santé, Femelle, Humains, Mobilité réduite, Société américaine du cancer, Sujet âgé, Survivants, Tumeurs du sein, États-Unis d'Amérique, Études longitudinales, Études prospectives, Évaluation de l'incapacité.
- Wicri :
- geographic : États-Unis.
English descriptors
- KwdEn :
- Adult, Aged, American Cancer Society, Breast Neoplasms (complications), Breast Neoplasms (diagnosis), Breast Neoplasms (rehabilitation), Congresses as Topic, Cost-Benefit Analysis, Disability Evaluation, Female, Health Care Costs, Humans, Longitudinal Studies, Lymphedema (economics), Lymphedema (etiology), Lymphedema (rehabilitation), Middle Aged, Mobility Limitation, Musculoskeletal Diseases (economics), Musculoskeletal Diseases (etiology), Musculoskeletal Diseases (rehabilitation), Physical Therapy Modalities (economics), Prospective Studies, Survivors, United States.
- MESH :
- geographic : United States.
- complications : Breast Neoplasms.
- diagnosis : Breast Neoplasms.
- economics : Lymphedema, Musculoskeletal Diseases, Physical Therapy Modalities.
- etiology : Lymphedema, Musculoskeletal Diseases.
- rehabilitation : Breast Neoplasms, Lymphedema, Musculoskeletal Diseases.
- Adult, Aged, American Cancer Society, Congresses as Topic, Cost-Benefit Analysis, Disability Evaluation, Female, Health Care Costs, Humans, Longitudinal Studies, Middle Aged, Mobility Limitation, Prospective Studies, Survivors.
Abstract
For this article, the authors examined the cost implications of the prospective surveillance model (PSM) for breast cancer (BC) survivors, a comprehensive framework designed to preemptively reduce the incidence and virulence of common impairments. The model clearly has the potential of providing significant benefits. However, its accompanying costs and resource requirements remain unclear and may be substantial. Thus, it is critical to examine which BC survivors may benefit from the PSM, how much they will benefit, and the costs of this benefit before its implementation. Because the PSM is not rigidly prescriptive, its examination must allow for different scenarios with emphasis on 4 critical determinants of cost--whether all or only high-risk BC survivors participate, assessment frequencies and locations, the credentials of the assessors, and requirements for supportive equipment. Another issue is the distribution of its cost: hypothetical implementation strategies vary widely in their distribution of fiscal burden across key stakeholders--survivors, providers, and payers--whose financial responsibilities will be an important factor in whether and how rapidly they adopt the PSM. Accurate valuation of the PSM will require capture of direct and indirect cost savings and benefits. Currently, a lack of data regarding these parameters, as well as outcomes that can be reliably attributed to the PSM, impedes cost-effectiveness analyses. Because the PSM may enhance many health state characteristics, assessments that integrate overall composite measures with evaluations of common, discrete impairments may be required to comprehensively assess its benefits.
DOI: 10.1002/cncr.27473
PubMed: 22488706
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002168
- to stream PubMed, to step Curation: 002168
- to stream PubMed, to step Checkpoint: 002168
- to stream Ncbi, to step Merge: 004C57
- to stream Ncbi, to step Curation: 004C57
- to stream Ncbi, to step Checkpoint: 004C57
- to stream Main, to step Merge: 004422
- to stream Main, to step Curation: 004403
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cost considerations regarding the prospective surveillance model for breast cancer survivors.</title><author><name sortKey="Cheville, Andrea L" sort="Cheville, Andrea L" uniqKey="Cheville A" first="Andrea L" last="Cheville">Andrea L. Cheville</name><affiliation wicri:level="1"><nlm:affiliation>Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, Minnesota 55905, USA. cheville.andrea@mayo.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, Minnesota 55905</wicri:regionArea><wicri:noRegion>Minnesota 55905</wicri:noRegion></affiliation></author><author><name sortKey="Nyman, John A" sort="Nyman, John A" uniqKey="Nyman J" first="John A" last="Nyman">John A. Nyman</name></author><author><name sortKey="Pruthi, Sandhya" sort="Pruthi, Sandhya" uniqKey="Pruthi S" first="Sandhya" last="Pruthi">Sandhya Pruthi</name></author><author><name sortKey="Basford, Jeffrey R" sort="Basford, Jeffrey R" uniqKey="Basford J" first="Jeffrey R" last="Basford">Jeffrey R. Basford</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:22488706</idno><idno type="pmid">22488706</idno><idno type="doi">10.1002/cncr.27473</idno><idno type="wicri:Area/PubMed/Corpus">002168</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002168</idno><idno type="wicri:Area/PubMed/Curation">002168</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002168</idno><idno type="wicri:Area/PubMed/Checkpoint">002168</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002168</idno><idno type="wicri:Area/Ncbi/Merge">004C57</idno><idno type="wicri:Area/Ncbi/Curation">004C57</idno><idno type="wicri:Area/Ncbi/Checkpoint">004C57</idno><idno type="wicri:Area/Main/Merge">004422</idno><idno type="wicri:Area/Main/Curation">004403</idno><idno type="wicri:Area/Main/Exploration">004403</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cost considerations regarding the prospective surveillance model for breast cancer survivors.</title><author><name sortKey="Cheville, Andrea L" sort="Cheville, Andrea L" uniqKey="Cheville A" first="Andrea L" last="Cheville">Andrea L. Cheville</name><affiliation wicri:level="1"><nlm:affiliation>Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, Minnesota 55905, USA. cheville.andrea@mayo.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, Minnesota 55905</wicri:regionArea><wicri:noRegion>Minnesota 55905</wicri:noRegion></affiliation></author><author><name sortKey="Nyman, John A" sort="Nyman, John A" uniqKey="Nyman J" first="John A" last="Nyman">John A. Nyman</name></author><author><name sortKey="Pruthi, Sandhya" sort="Pruthi, Sandhya" uniqKey="Pruthi S" first="Sandhya" last="Pruthi">Sandhya Pruthi</name></author><author><name sortKey="Basford, Jeffrey R" sort="Basford, Jeffrey R" uniqKey="Basford J" first="Jeffrey R" last="Basford">Jeffrey R. Basford</name></author></analytic><series><title level="j">Cancer</title><idno type="eISSN">1097-0142</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>American Cancer Society</term><term>Breast Neoplasms (complications)</term><term>Breast Neoplasms (diagnosis)</term><term>Breast Neoplasms (rehabilitation)</term><term>Congresses as Topic</term><term>Cost-Benefit Analysis</term><term>Disability Evaluation</term><term>Female</term><term>Health Care Costs</term><term>Humans</term><term>Longitudinal Studies</term><term>Lymphedema (economics)</term><term>Lymphedema (etiology)</term><term>Lymphedema (rehabilitation)</term><term>Middle Aged</term><term>Mobility Limitation</term><term>Musculoskeletal Diseases (economics)</term><term>Musculoskeletal Diseases (etiology)</term><term>Musculoskeletal Diseases (rehabilitation)</term><term>Physical Therapy Modalities (economics)</term><term>Prospective Studies</term><term>Survivors</term><term>United States</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Analyse coût-bénéfice</term><term>Congrès comme sujet</term><term>Coûts des soins de santé</term><term>Femelle</term><term>Humains</term><term>Lymphoedème (rééducation et réadaptation)</term><term>Lymphoedème (économie)</term><term>Lymphoedème (étiologie)</term><term>Maladies ostéomusculaires (rééducation et réadaptation)</term><term>Maladies ostéomusculaires (économie)</term><term>Maladies ostéomusculaires (étiologie)</term><term>Mobilité réduite</term><term>Société américaine du cancer</term><term>Sujet âgé</term><term>Survivants</term><term>Techniques de physiothérapie (économie)</term><term>Tumeurs du sein ()</term><term>Tumeurs du sein (diagnostic)</term><term>Tumeurs du sein (rééducation et réadaptation)</term><term>États-Unis d'Amérique</term><term>Études longitudinales</term><term>Études prospectives</term><term>Évaluation de l'incapacité</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>United States</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Lymphedema</term><term>Musculoskeletal Diseases</term><term>Physical Therapy Modalities</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Lymphedema</term><term>Musculoskeletal Diseases</term></keywords><keywords scheme="MESH" qualifier="rehabilitation" xml:lang="en"><term>Breast Neoplasms</term><term>Lymphedema</term><term>Musculoskeletal Diseases</term></keywords><keywords scheme="MESH" qualifier="rééducation et réadaptation" xml:lang="fr"><term>Lymphoedème</term><term>Maladies ostéomusculaires</term><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Lymphoedème</term><term>Maladies ostéomusculaires</term><term>Techniques de physiothérapie</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Lymphoedème</term><term>Maladies ostéomusculaires</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>American Cancer Society</term><term>Congresses as Topic</term><term>Cost-Benefit Analysis</term><term>Disability Evaluation</term><term>Female</term><term>Health Care Costs</term><term>Humans</term><term>Longitudinal Studies</term><term>Middle Aged</term><term>Mobility Limitation</term><term>Prospective Studies</term><term>Survivors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Analyse coût-bénéfice</term><term>Congrès comme sujet</term><term>Coûts des soins de santé</term><term>Femelle</term><term>Humains</term><term>Mobilité réduite</term><term>Société américaine du cancer</term><term>Sujet âgé</term><term>Survivants</term><term>Tumeurs du sein</term><term>États-Unis d'Amérique</term><term>Études longitudinales</term><term>Études prospectives</term><term>Évaluation de l'incapacité</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>États-Unis</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">For this article, the authors examined the cost implications of the prospective surveillance model (PSM) for breast cancer (BC) survivors, a comprehensive framework designed to preemptively reduce the incidence and virulence of common impairments. The model clearly has the potential of providing significant benefits. However, its accompanying costs and resource requirements remain unclear and may be substantial. Thus, it is critical to examine which BC survivors may benefit from the PSM, how much they will benefit, and the costs of this benefit before its implementation. Because the PSM is not rigidly prescriptive, its examination must allow for different scenarios with emphasis on 4 critical determinants of cost--whether all or only high-risk BC survivors participate, assessment frequencies and locations, the credentials of the assessors, and requirements for supportive equipment. Another issue is the distribution of its cost: hypothetical implementation strategies vary widely in their distribution of fiscal burden across key stakeholders--survivors, providers, and payers--whose financial responsibilities will be an important factor in whether and how rapidly they adopt the PSM. Accurate valuation of the PSM will require capture of direct and indirect cost savings and benefits. Currently, a lack of data regarding these parameters, as well as outcomes that can be reliably attributed to the PSM, impedes cost-effectiveness analyses. Because the PSM may enhance many health state characteristics, assessments that integrate overall composite measures with evaluations of common, discrete impairments may be required to comprehensively assess its benefits.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country></list><tree><noCountry><name sortKey="Basford, Jeffrey R" sort="Basford, Jeffrey R" uniqKey="Basford J" first="Jeffrey R" last="Basford">Jeffrey R. Basford</name><name sortKey="Nyman, John A" sort="Nyman, John A" uniqKey="Nyman J" first="John A" last="Nyman">John A. Nyman</name><name sortKey="Pruthi, Sandhya" sort="Pruthi, Sandhya" uniqKey="Pruthi S" first="Sandhya" last="Pruthi">Sandhya Pruthi</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Cheville, Andrea L" sort="Cheville, Andrea L" uniqKey="Cheville A" first="Andrea L" last="Cheville">Andrea L. Cheville</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004403 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004403 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:22488706
|texte= Cost considerations regarding the prospective surveillance model for breast cancer survivors.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:22488706" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |